Skip to content

A study to clarify the relationship between FDG PET findings and heart disease for the purpose of tumor diagnosis

Prospective study on the association between myocardial accumulation and heart disease in FDG PET for tumor diagnosis Myocardial Accumulation and Heart Disease in FDG PET for Tumor Diagnosis - A Prospective Study on the Association between Tumor FDG PET Findings and Heart Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042941
Enrollment
300
Registered
2021-04-01
Start date
2021-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease.

Interventions

Sponsors

Tohoku University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Men and women over 60 years old (2) Scheduled to undergo FDG PET examination as a pre-treatment test for esophageal cancer or lung cancer. (3) Have at least 3 of the following coronary risk factors (male, hypertension(systolic blood pressure >=130 mmHg), type 2 diabetes mellitus, hypertriglyceridemia (TG >=150 mg/dL), hypoHDLemia (HDL<40 mg/dL), smoking history, obesity (BMI>=25)). (4) The contents of this study will be explained in writing and orally, and the subject will understand and give written consent. (5) Good general health (PS2 or less)

Exclusion criteria

Exclusion criteria: (1) History of thoracic surgery or radiation to the chest (2) Difficult to perform stress myocardial perfusion scintigraphy before treatment for esophageal cancer due to schedule (3) Patients who are not eligible for PET scan or stress myocardial scintigraphy in their regular practice Pregnancy and lactation: Pregnant and lactating women, or those who may be pregnant. History of adverse reaction or allergy related to FDG administration in the past 18F-FDG-PET examination. Prior history of adverse reactions or allergies related to drugs used in myocardial perfusion scintigraphy. Treatment for unstable angina, complete atrioventricular block, or asthma (4) Chest pain suggestive of angina pectoris. (5) Previously indicated coronary artery stenosis of 90% or more by coronary CT and untreated (6) Other conditions considered difficult to participate in the study Difficulty in resting on a bed for 30 minutes Inability to understand the content of the study due to psychosis or psychiatric symptoms Patients who fall into any of the above categories are not eligible for the study.

Design outcomes

Primary

MeasureTime frame
To compare myocardial FDG accumulation patterns with the results of cardiac examinations to identify cardiac FDG accumulation patterns that are predictive of heart disease.

Secondary

MeasureTime frame
Myocardial FDG accumulation is known to be affected by fasting time and diet prior to FDG PET examination, and the optimal pre-test conditions will be discussed.

Countries

Japan

Contacts

Public ContactMioko Saito

Tohoku University Hospital Department of Diagnostic Radiology

mioko.yoshida.b8@tohoku.ac.jp022-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026